thalidomide has been researched along with Experimental Hepatoma in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was orally administered for 5 days." | 1.37 | Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model. ( Murata, K; Nitta, N; Nitta-Seko, A; Ohta, S; Otani, H; Sonoda, A; Takahashi, M; Tsuchiya, K, 2011) |
| "Treatment with thalidomide resulted in a significant decrease in AUC, PI and IMAX compared with Group A (p<0." | 1.37 | Quantitative evaluation of viable tissue perfusion changes with contrast-enhanced greyscale ultrasound in a mouse hepatoma model following treatment with different doses of thalidomide. ( Cao, LH; Han, F; Li, AH; Liu, M; Luo, RZ; Wu, PH; Zheng, W; Zhou, JH, 2011) |
| "Quantification of tumor blood flow by using contrast-enhanced destruction-replenishment US shows the potential to guide drug dosage during antiangiogenic therapy." | 1.37 | Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US. ( Cao, LH; Han, F; Li, AH; Liu, JB; Liu, M; Luo, RZ; Zheng, W; Zhou, JH, 2011) |
| "Thalidomide cannot inhibit VEGF mRNA expression of grafted H22 tumor in mouse." | 1.32 | [Effect of thalidomide on tumor growth in mouse hepatoma H22 model]. ( Lu, ZJ; Zhai, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ao, M | 1 |
| Xiao, X | 1 |
| Ao, Y | 1 |
| Chen, F | 1 |
| De Keyzer, F | 1 |
| Feng, YB | 1 |
| Cona, MM | 1 |
| Yu, J | 1 |
| Marchal, G | 1 |
| Oyen, R | 1 |
| Ni, YC | 1 |
| Yao, DF | 1 |
| Yu, HB | 1 |
| Shen, JJ | 1 |
| Wang, YL | 1 |
| Wu, XH | 1 |
| Qiu, LW | 1 |
| Wu, W | 1 |
| Zhou, J | 1 |
| Zheng, W | 3 |
| Cao, L | 1 |
| Liu, M | 3 |
| Han, F | 3 |
| Li, A | 1 |
| Nitta-Seko, A | 1 |
| Nitta, N | 1 |
| Sonoda, A | 1 |
| Otani, H | 1 |
| Tsuchiya, K | 1 |
| Ohta, S | 1 |
| Takahashi, M | 1 |
| Murata, K | 1 |
| Zhou, JH | 2 |
| Cao, LH | 2 |
| Luo, RZ | 2 |
| Wu, PH | 1 |
| Li, AH | 2 |
| Liu, JB | 1 |
| Zhai, Y | 1 |
| Lu, ZJ | 1 |
| Yang, YM | 1 |
| Du, GJ | 1 |
| Lin, HH | 1 |
| Zhang, ZL | 1 |
| Liu, ZS | 1 |
| Sun, Q | 1 |
10 other studies available for thalidomide and Experimental Hepatoma
| Article | Year |
|---|---|
Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Synergism; Hep G2 Cells; Humans; Lipoproteins, LDL; | 2018 |
Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Diffusion Magnetic | 2013 |
[The effect of thalidomine-induced NF-kappa B activation on malignant transformation of hepatocytes].
Topics: 2-Acetylaminofluorene; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Immunohistochemi | 2009 |
Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Contrast Media; Image Enhancement; Image Interpr | 2010 |
Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; | 2011 |
Quantitative evaluation of viable tissue perfusion changes with contrast-enhanced greyscale ultrasound in a mouse hepatoma model following treatment with different doses of thalidomide.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Contrast Media; Dose-Response Relations | 2011 |
Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Carboxymethylcellulose Sodium; Carcinoma, He | 2011 |
[Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
Topics: Angiogenesis Inhibitors; Animals; Body Weight; Carcinoma, Hepatocellular; Disease Models, Animal; Fl | 2003 |
Experimental study of thalidomide for treatment of murine hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Synergism; Female; Liver Neoplasms, Experimental; | 2005 |
[Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice].
Topics: Animals; Antigens, CD34; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Ma | 2005 |